Definitive Contract 75A50123C00064
Award Date
9/25/23
Potential Completion Date
1/30/26
Potential Value
$748K
Awardee
Partner Therapeutics, Inc.
Ultimate Awardee
Not listed
PSC Category
AN15 - Health R&D Services; Health Care Services; Expenses For R&D Facilities And Major Equipment
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lexington, MA 02421, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This contract award to Partner Therapeutics, Inc. is for a Task Order under the HHS Colony Stimulating Factor 2013-2018 Indefinite Delivery/Indefinite Quantity (ID/IQ) contract. The task order, valued at $13,943,972.12, is for the acquisition of a Colony Stimulating Factor (G- or GM-CSF) as a medical countermeasure for neutropenia. The contract is a Firm Fixed Price Delivery Order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the Department of...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded Esperovax Inc. a $484,643 firm fixed price definitive contract to develop host-directed therapeutic candidates for mitigating long-term effects of respiratory distress. The contract was awarded under Special Instructions 019 of the Easy Broad Agency Announcement BAA-20-100-SOL-0002, which sought proposals for candidates aiding long-term outcomes from lung injury through Area of...
This is a $62,511,942.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The contract is for the development of an anti-Sudan ebolavirus medical countermeasure, a critical public health and national security priority. Mapp Biopharmaceutical has a strong...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a $293,443,870.00 definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract is for the provision of therapeutic interventions and medical countermeasures against infectious diseases and biothreats, including viral hemorrhagic fevers like Ebola, Marburg, and Lassa, as well as botulinum neurotoxin. Mapp...
This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract focuses...
The U.S. Department of Health and Human Services (HHS), through the Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $630,384,987.00 firm-fixed-price definitive contract to Emergent BioDefense Operations Lansing LLC for the advanced research and development of a smallpox antiviral drug. This award is not associated with a set-aside contract and is part of ASPR's broader efforts to procure and stockpile alternative smallpox antivirals. The original procurement was...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $749,000.00 Firm Fixed Price contract to Medicinova, Inc. to support the "REPURPOSING DRUGS IN RESPONSE TO CHEMICAL THREATS (REDIRECT)" effort. This contract is not set aside and was awarded under the Easy Broad Agency Announcement (EZ-BAA) solicitation released by ASPR's Division of Research, Innovation, and Ventures (DRIVe). The contract has a period of...
This firm fixed-price contract, valued at $762,812,695, was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company. The contract is for the development of medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response...